

Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM

PCOM Scholarly Papers

8-24-2019

A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation: Clinical Study and Literature Review.

Jian Pang

Linang Wang

Jing Xu

Qiubo Xie

Qjuli Liu

See next page for additional authors

Follow this and additional works at: https://digitalcommons.pcom.edu/scholarly_papers

 Part of the [Oncology Commons](#)

Recommended Citation

Pang, Jian; Wang, Linang; Xu, Jing; Xie, Qiubo; Liu, Qjuli; Tong, Dali; Liu, Gaolei; Huang, Yiqiang; Yang, Xingxia; Pan, Jinhong; Yan, Xiaochu; Ma, Qiang; Zhang, Dianzheng; and Jiang, Jun, "A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation: Clinical Study and Literature Review." (2019). *PCOM Scholarly Papers*. 2014.
https://digitalcommons.pcom.edu/scholarly_papers/2014

This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Authors

Jian Pang, Linang Wang, Jing Xu, Qiubo Xie, Qiuli Liu, Dali Tong, Gaolei Liu, Yiqiang Huang, Xingxia Yang, Jinhong Pan, Xiaochu Yan, Qiang Ma, Dianzheng Zhang, and Jun Jiang

A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation:
Clinical Study and Literature Review

Jian Pang , Linang Wang , Jing Xu , Qiubo Xie , Qiuli Liu ,
Dali Tong , Gaolei Liu , Yiqiang Huang , Xingxia Yang ,
Jinhong Pan , Xiaochu Yan , Qiang Ma , Dianzheng Zhang ,
Jun Jiang

PII: S0090-4295(19)30734-4
DOI: <https://doi.org/10.1016/j.urology.2019.08.016>
Reference: URL 21734

To appear in: *Urology*

Received date: 13 June 2019
Revised date: 7 August 2019
Accepted date: 10 August 2019

Please cite this article as: Jian Pang , Linang Wang , Jing Xu , Qiubo Xie , Qiuli Liu ,
Dali Tong , Gaolei Liu , Yiqiang Huang , Xingxia Yang , Jinhong Pan , Xiaochu Yan , Qiang Ma ,
Dianzheng Zhang , Jun Jiang , A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation: Clinical
Study and Literature Review, *Urology* (2019), doi: <https://doi.org/10.1016/j.urology.2019.08.016>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service
to our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and
all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier Inc.



A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation:**Clinical Study and Literature Review**

Jian Pang¹, Linang Wang¹, Jing Xu¹, Qiubo Xie¹, Qiuli Liu¹, Dali Tong¹, Gaolei Liu¹,
Yiqiang Huang¹, Xingxia Yang¹, Jinhong Pan², Xiaochu Yan³, Qiang Ma⁴,
Dianzheng Zhang⁵ and Jun Jiang^{1*}

¹Department of Urology, Institute of Surgery Research, Daping Hospital, Army Medical University, 10#, Changjiang Zhilu, Yuzhong District, Chongqing 400042, PR China

²Department of Urology, Southwest Hospital, Army Medical University, 30#, Gaotanyan Zhengjie, Shapingba District, Chongqing 400038, PR China

³Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 30#, Gaotanyan Zhengjie, Shapingba District, Chongqing 400038, PR China

⁴Department of Pathology, Institute of Surgery Research, Daping Hospital, Army Medical University, 10#, Changjiang Zhilu, Yuzhong District, Chongqing 400042, PR China

⁵Department of Biomedical Sciences, Philadelphia College of Osteopathic Medicine, 4170 City Ave, Philadelphia, PA 19131, USA

Declarations of interest: none

***Corresponding author:**

Jun Jiang

10#, Changjiang Zhilu, Yuzhong District, Chongqing 400042, PR China

Telephone: +86-023-68757946; Fax: +86-023-68757946;

Email: jiangjun_64@163.com

Jian Pang: pangjian_16@163.com

Linang Wang: billwg32@hotmail.com

Jing Xu: jingxu8023@163.com

Qiubo Xie: xieqiubojiu@126.com

Qiuli Liu: liuqiuli900827@163.com

Dali Tong: tongdali1985@163.com

Gaolei Liu: liumcz@foxmail.com

Yiqiang Huang: huangyiqiang105@163.com

Xingxia Yang: yang_xing_xia@163.com

Jinhong Pan: panjh765@163.com

Xiaochu Yan: yxcwq@163.com

Qiang Ma: 375640711@qq.com

Dianzheng Zhang: dianzhengzh@pcom.edu

Keywords: Renal cell carcinoma. Tuberous sclerosis complex. *TSC2*. mTORC1.

Clear cell renal cell carcinoma.

Word counts for the Abstract: 140

Word counts for the manuscript text: 2651

Acknowledgment

The authors are grateful to the patient and her family.

Funding

This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure

The Institutional Review Board of Daping Hospital of Third Military Medical University waived the IRB approval for the study; moreover, for the use of medical records and related images, the written informed consent was obtained from the patients before the publication of the study. The authors have nothing to disclose.

Abstract

Objectives: To elucidate the effect of the biallelic somatic *TSC2* mutations, identified in one adolescent patient, in renal cell carcinoma (RCC). Methods: Mutation analyses, immunohistochemistry and real-time polymerase chain reaction (PCR) were conducted. Results: Two novel somatic mutations of *TSC2* in unilateral and solitary RCC samples from a 14-year-old female were identified. The pathological features suggest the tumor as a clear-cell renal cell carcinoma. In addition, immunohistochemistry revealed elevated levels of phosphorylated S6K1. Results from *in vitro* cellular experiments suggest that the mutant *TSC2* proteins were quickly degraded and they failed to repress the phosphorylation of S6K1 and STAT3, which leads to constitutive activation of mTORC1 pathway and ultimately cause the development of RCC. Conclusions: Detecting *TSC2* mutation in patients with early RCC onset would be beneficial and mTOR inhibitor could be a therapeutic option for *TSC2* mutation-induced RCC.

Introduction

Renal cell carcinoma (RCC) represents about 90% of renal malignancies, which is the 13th most common malignancy among all cancers. Approximately 2-3% of RCC occurs in patients with hereditary diseases including von Hippel-Lindau (VHL) syndrome, hereditary papillary renal cell carcinoma, and Birt-Hogg-Dube' syndrome [1]. In addition, 2-4% of tuberous sclerosis (TSC) patients suffer from RCC, which is higher than the estimated incidence among the general population. Multiple lines of evidence suggest that loss of function of either *TSC1* or *TSC2* could result in RCC [2-4].

The *TSC1* and *TSC2* genes are located on 9q34 and 16q13.3, respectively [5]. The protein complex composed of hamartin and tuberin, which is translated from *TSC1* and *TSC2* respectively, possesses GTPase activity responsible for turning GTP-Rheb to GDP-Rheb. Therefore, both *TSC1* and *TSC2* were also known as cancer suppressors partially due to their inhibitory role on mammalian target of rapamycin complex 1 (mTORC1). Mechanistically, loss-of-function mutations in *TSC1* and/or *TSC2* result in inactivation of the hamartin-tuberin complex and subsequently inactivate GTPase and ultimately lead to constitutive activation of the mTORC1 pathway [3]. TSC is an autosomal dominant disease and almost all organs in these patients were affected [5] characterized by facial angiofibroma, seizures, and cognitive disability. TSC also can cause renal lesions including renal cell carcinoma [6]. Since the first reported RCC in a patient with TSC in 1986 [7], numerous cases of RCC have

been reported in familial TSC with germline mutations in either *TSC1* or *TSC2*. However, cases of RCC due to a somatic mutation of *TSC2* is relatively rare. Here we present a case of clear cell renal cell carcinoma (ccRCC) in an adolescent with two novel biallelic somatic mutations in *TSC2*.

Material and Methods

2.1 Patient presentation

A 14-year-old female was referred to the Southwest Hospital on July 23, 2017, due to the finding of a mass in the upper pole of her left kidney identified during an ultrasound test. Kidney tumor was later diagnosed based on the abdominal computed tomography (CT) scan. The laboratory tests did not reveal any other notable abnormalities. A robot-assisted nephron-sparing enucleation was conducted on July 26, 2017, with a da Vinci surgical system and a 3.0×3.0 cm mass was excised. No sign of recurrence nor metastasis was seen in repeat CT scans during the reexamination conducted nine months after the surgery. Based on the clinical manifestation^[8], mutation analyses were performed to determine whether there are germline or somatic mutations responsible for the ccRCC. We collected both peripheral blood and tumor samples for mutation analyses. Mutations in several potential oncogenesis-associated genes (supplement table 1) were screened using ER-seq (Gene+, China). To confirm

the *TSC2* mutation, polymerase chain reaction (PCR) was conducted on the patient's DNA with primers specifically designed for *TSC* gene amplification, the PCR products were sub-cloned into a pMD18-T vector (D103A, TAKARA, Shiga, Japan), and finally Sanger sequencing was conducted. The informed consent was obtained from the patient and their parents, and all procedures performed in this study were in accordance with the standards of institutional research committee, and approved by the Research Ethics Committee of Daping Hospital, Third Military Medical University.

2.2 Immunohistochemistry

Immunohistochemistry was conducted as described ^[9]. After deparaffinization and rehydration, slices were retrieved and incubated with primary antibodies against *TSC2* (Santa Cruz, USA), *VHL* (OriGene, MD, USA), phosphorylated *S6K1* (p-S6K1) (Cell Signaling Technology, USA), *HIF1 α* (Abcam, USA), *HIF2 α* (OriGene, MD, USA), *EPO* (Santa Cruz, USA), *SDHB* (Proteintech, USA) and *VEGF* (OriGene, MD, USA) followed by incubation with HRP-labeled goat anti-mouse/rabbit IgG. In addition, the samples from a patient with Von Hippel-Lindau syndrome were used as a positive control.

2.3 Cell culture

Rat uterine leiomyoma-derived *Tsc2*-null cells, kindly provided by Dr. Hongbing

Zhang of Peking Union Medical College, were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) (Gibco) at 37°C with 5% CO₂.

2.4 Transient transfection

Since the two mutations identified in this patient were not reported previously, the function of them was elusive. To identify the function, plasmids containing either *TSC2* mutations or wild type *TSC2* were constructed (Mutant 1: c.1039-1049delAAGAAGTATAG in exon 11, Mutant 2: c.2721insT in exon 24) and transiently transfected into *TSC2*-null cells with Lipofectamine 3000 reagent (Invitrogen).

2.5 Western blotting

Lysates were collected from cells transfected with different plasmids and separated on SDS-PAGE followed by western blotting assay described previously^[10] using the primary antibodies against *TSC2* (Abcam, USA), *S6K1* (Abcam, USA), p-*S6K1* (T389+T412) (Abcam USA), *STAT3* (Abcam USA), phosphorylated *STAT3* (p-*STAT3*) (Cell signaling) and β -actin (Cell signaling).

2.6 Real-time PCR

According to the manufacturer's protocol, RNA and DNA were isolated from cells with Ultrapure RNA Kit (CWBio) and TIANamp Genomic DNA Kit (TIANGEN),

respectively. One microgram RNA was subjected to reverse transcription with Hiscript III RT SuperMix for qPCR (Vazyme), following the manufacturer's protocol. As previously described ^[11], real-time polymerase chain reaction (PCR) was performed with the LightCycler[®]96 System (Roche Diagnostics GmbH, Roche Applied Science, Mannheim, Germany) using AceQ qPCR SYBR Green Master Mix (Vazyme). The primers of *TSC2* were described below: 5'-CGAGTCAAACAAGCCAATC-3' (forward) and 5'-ATCGTGCCAGCAGTAGGTG-3' (reverse). PCR data were analyzed using Graph Pad Prism (Graph Pad Software, San Diego, California, USA).

2.7 Literature Review

Literature published between 1966 and June 1 2019, were searched in the Medline database. TSC AND kidney neoplasms (MeSH Terms) AND carcinoma renal cell (MeSH Terms) were used for searching related cases and articles. All RCC cases with *TSC* mutations were included in the review if they meet the following criteria: (i) RCC with *TSC* mutation; (ii) pathological examination was applied to verify the diagnosis; and (iii) gene mutations were analyzed and confirmed.

Results

3.1 biallelic somatic mutations were identified in a patient with RCC

A diagnosis of T1N0M0 kidney tumor was made based on the heterogeneous enhancement of the mass in the abdominal computed tomography (CT) scan (Figure 1A). Tumor samples from a patient with VHL syndrome showed specific ccRCC morphology characterized by transparent and empty cytoplasm, well-defined cell borders and thin-walled vessels. In the tumor samples of our patient with *TSC2* mutation, round and regular nuclei, cytoplasm with granular eosinophilic material around the nucleus and thin-walled vessels were shown in hematoxylin-eosin staining, suggesting a ccRCC, Furhman Grade 3 (Figure 1C). In addition, immunohistochemical staining results of the tumor samples with *TSC2* mutation also showed positive CK, Vimentin, CD10, RCC staining, and negative CA9, CK7 and TFE-3 staining (data not shown). Two pathologists confirmed these results independently.

Considering the early onset age and clinical characteristics, hereditary RCC should be identified. Susceptibility genes highly associated with RCC oncogenesis (supplement table 1 and supplement table 2) were examined in both peripheral blood and tumor samples. No germline mutations were observed, while two novel somatic mutations in *TSC2* were identified in the tumor, but not the peripheral blood. These biallelic frameshift mutations were not found in the Catalogue Of Somatic Mutations In Cancer (<http://cancer.sanger.ac.uk>). Therefore we conclude that we identified a novel 11-base deletion of 1039_1049 (c.1039-1049del AAGAAGTATAG) in exon 11 which leads to a frameshift (p.K347Efs*36) and a novel 1-base insertion at base 2721

(c.2721insT) in exon 24 which also leads to a frameshift (p.V909Cfs*6) (Figure 1B).

Of note, no somatic nor germline mutation was found in the other oncogenesis genes examined (data are not shown).

3.2 Higher p-S6K1 expression in tumor cells with mutant *TSC2*

It appears that the frameshift mutations in either exon 11 or 24 of *TSC2* would result in truncated *TSC2* protein which might be loss-of-function. We have also noticed that in the tumor cells with *TSC2* mutation the *TSC2* staining is negative. On the contrary, the *TSC2* staining in samples of another patient with VHL syndrome is positive. Next, we examined the levels of downstream of *TSC2* (p-S6K1) in tumor samples. The results substantiated that the mutant *TSC2* proteins were loss-of-function evidenced by positive staining of p-S6K1 in the patient with *TSC2* mutations but negative staining with VHL syndrome. The VHL staining in both samples is positive with similar intensities (Fig 1C). In addition, the papillary renal cell carcinoma associated-gene *SDHB* is not only expressed but with comparable intensities in these samples (data not shown).

3.3 The effect of *TSC2* mutations on the levels of p-S6K1 and p-STAT3 *in vitro*

To elucidate the relationship between the above-mentioned *TSC2* mutations and RCC,

we first tried to express either wild type or mutant TSC2 in *TSC2*-null cells by transient transfection of a plasmid expressing corresponding TSCs. The plasmids expressing either wild type or mutant TSC2 were successfully delivered to the cells and transcribed into their corresponding mRNAs evidenced by positive results from PCR (Figure 2B and 2C). However, only the wild type, but not the mutant, TSC2 were detectable by western blot assays (Figure 2A). Since the results from PCR indicate that the transfected plasmids were successfully transcribed, we speculate that the mutant and presumably misfolded TSC2s is quickly degraded in the cells. Consequently, phosphorylation of STAT3 and S6K1 in *TSC2*-null cells were repressed only when they were transfected with the plasmid expressing the wild type, but not the mutant, TSC2. Of note, the levels of STAT3, S6K1, and β -actin were comparable among in these experiments. These results altogether suggest that the mutant TSC2 might be quickly degraded and consequently lost repression of the downstream pathways, which ultimately leads to RCC oncogenesis ^[2-4].

3.4 Literature Review

Among the 59 articles retrieved by searching the Medline database published between (1969 and 2017), 33 were included in this review. In 1986, Graves et al reported the first case of TSC associated RCC ^[7]. Since then, dozens of RCC cases associated with TSC have been reported although gene sequencing for the specific mutations was not conducted. In 1995, Sampson et al reported RCC accompanied with a *TSC1* mutation in two sisters of the same family who also suffered from TSC ^[12]. In 1996, Bjornsson

et al reported a case of RCC in a patient with TSC due to a loss-of-heterozygosity (LOH) in *TSC2* ^[13]. In 2011, Kucejova et al identified a somatic mutation in *TSC1* in three cases of TSC-associated ccRCC ^[14]. Not until 2015, have the first two cases of TSC-associated RCC with a somatic mutation in *TSC2* been reported by Tyburczy et al. Also in the same article, the second-hit theory was introduced to explain *TSC2* inactivation ^[15]. Samer Alsidawi et al described a patient with *TSC2*-associated metastatic RCC and showed the efficacy of mTOR inhibition in therapy ^[16]. Seven patients with eosinophilic solid and cystic renal cell carcinoma were reported with somatic biallelic loss of *TSC* gene ^[17]. So far, only 26 cases of RCC with *TSC* mutation have been reported and the characteristics of these patients were summarized in Table 1.

Discussion

Approximately 2-3% of RCC were considered as hereditary diseases, including von Hippel-Lindau (VHL) syndrome, hereditary papillary renal cell carcinoma and Birt-Hogg-Dube syndrome commonly ^[1]. In addition, about 2-4% of TSC patients also suffer from RCC ^[2-4]. It is well established that germline mutations in *TSC1/2* can cause RCC ^[13, 18-20]. Somatic inactivation of *TSC1/2* either due to heterozygous loss of *TSC1* or mutations in *TSC1* and *TSC2* occurs in 1–2% of adult RCC patients ^[21]. However, biallelic somatic inactivation of *TSC2* associated RCC in an adolescent is rare. Here we reported RCC in a female adolescent with two novel somatic inactivating mutations in *TSC2*. Additionally, results from *in vitro* experiments

demonstrated that the mutant TSC2s were incapable of repressing its downstream pathways.

The classic two-hit theory is a widely accepted mechanism in the oncogenesis of patients with TSC [3, 6, 22]. Tyburczy et al found that patients with TSC carrying germline mutations in *TSC1* or *TSC2*. The second hit of the remaining allele was found in renal cell carcinoma [15]. Potter et al reported two somatic *TSC2* mutations in tumor samples from a 6-year-old female with RCC and methylmalonic acidemia [21]. Our findings in this report also strongly support the two-hit theory. Of note, Tyburczy *et al.* conducted next-generation sequencing on DNAs purified from blood/saliva and some skin biopsy samples of 53 TSC patients. They found that the majority (26 of 45, 58%) of the patients in this cohort have mosaic TSC mutations [23]. Although two distinct *TSC2* mutations have been identified in the tumor of the patient reported in this article, we cannot exclude the possibility that the tumor tissue is made of cells expressing the two *TSC2* mutations mosaically. Together with *TSC1*, *TSC2* forms a complex essential for GTPase-activating and by hydrolyzing GTP in RHEB to inactivate mTORC1 pathway [24]. Therefore, loss-of-function of *TSC2* results in accumulation of GTP-RHEB and constitutive activation of mTORC1 which subsequently upregulates p-S6K1 and p-STAT3. Each of these factors plays important roles in the oncogenesis of renal cell carcinoma [25, 26]. In the current case, we found that upregulated p-S6K1 was accompanied by the mutations of *TSC2* in immunohistochemical staining of the tumor sample. P-STAT3 and p-S6K1, the downstream targets of mTORC1, were

significantly elevated in *TSC2*-null cells transfected with plasmids expressing the *TSC2* mutants. These results suggest that *TSC2* mutation-caused mTORC1 pathway over-activation could be the underlying molecular mechanism for the development of ccRCC. Although plasmids expressing either wild type or mutant *TSC2* were successfully delivered and transcribed in *TSC2*-null cells (Figure 2B and 2C), the mutant *TSC2*s were undetectable in western blots. We hypothesized that the mutant *TSC2*s are misfolded and quickly degraded^[27]. However, this needs to be confirmed experimentally in future studies.

Renal lesions are the most frequent manifestation in patients with TSC with 70-80% having angiomyolipomas, 20% with renal cysts although RCC is much less common^[5]. In RCC patients with familial TSC, tumors often occur bilaterally with a tendency of early-onset. The average onset of RCC in patients with TSC is 28-year-old, 25 years earlier than that in the general population^[28]. The onset of RCC in the current case is 14, which is not only much earlier than that of the general population but also the average onset age in patients with TSC. Contrary to the general distribution pattern in most RCC patients with TSC, the tumor is unilateral (the left kidney) and solitary.

RCC in TSC generally shows histological heterogeneity^[29] with different subtypes of RCC including ccRCC, papillary RCC, chromophobe carcinoma, and oncocytomas^[6].

Among the 46 renal neoplasms from 19 TSC patients, Yang et al identified three subtypes: 52% are TSC-associated papillary RCC with a deficiency in succinate

dehydrogenase subunit B (SDHB); 33% showed morphological features similar to a hybrid oncocytic/chromophobe tumor (HOCT), and 15% remained unclassifiable ^[4]. However, Guo et al reported that among 57 RCCs from 18 patients with TSC, 59% of the tumor was similar to chromophobe RCC; 30% resemble “renal angiomyoadenomatous tumor” or “RCC with smooth muscle stroma”; 11% of the tumors exhibited a granular eosinophilic-macrocytic morphology ^[30]. These findings suggest that TSC-associated RCC has distinctive pathological features. In the current case, a ccRCC subtype characterized by the regular nucleus, thin-walled vessels, positive CK, Vimentin, CD10, RCC staining and negative CA9, CK7, TFE-3 staining was confirmed by two independent pathologists.

Inhibitors of the mTOR signaling pathway are FDA-approved therapeutic reagents for adult patients with relapsed or metastatic RCC ^[21]. Multiple lines of evidence suggest that gene mutations in the mTOR pathway (including *TSC1*, *TSC2*, and *mTOR*) respond well to mTOR inhibition ^[30]. Based on the elevated level of p-S6K1 and p-STAT3, we speculate that the mTOR pathway in the current case could be super active. Although no signs of recurrence nor metastatic in this patient were seen so far, we believe that mTOR inhibitor could be administered once the tumor recurs or the patient is under situations unsuitable for surgery. In summary, we reported a rare case of ccRCC with novel biallelic somatic mutations in *TSC2*. This provides new insight into the mechanism of RCC oncogenesis. In addition, genetic testing for a *TSC2* mutation in patients with early RCC onset could be beneficial in both diagnosis and

therapy. Finally, mTOR inhibitor could be a therapeutic option for *TSC2* mutation-induced RCC.

References

1. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. *European urology*. 2011;60:615-621.
2. Bernstein J, Robbins TO. Renal involvement in tuberous sclerosis. *Annals of the New York Academy of Sciences*. 1991;615:36-49.
3. Lam HC, Nijmeh J, Henske EP. New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. *J Pathol*. 2017;241:219-225.
4. Yang P, Cornejo KM, Sadow PM, et al. Renal cell carcinoma in tuberous sclerosis complex. *Am J Surg Pathol*. 2014;38:895-909.
5. Kida Y, Yamaguchi K, Suzuki H, et al. Tuberous sclerosis, associated with renal cell carcinoma and angiomyolipoma, in a patient who developed endstage renal failure after nephrectomy. *Clin Exp Nephrol*. 2005;9:179-182.
6. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *The New England journal of medicine*. 2006;355:1345-1356.
7. Graves N, Barnes WF. Renal cell carcinoma and angiomyolipoma in tuberous sclerosis: case report. *The Journal of urology*. 1986;135:122-123.
8. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. *Nature reviews. Disease primers*. 2017;3:17009.
9. Liu Q, Wang Y, Tong D, et al. A Somatic HIF2 α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review. *Endocrine Pathology*. 2017;28:1-8.
10. Liu Q, Tong D, Liu G, et al. Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta1/STAT3 axis-regulated EMT. *Cell Death Dis*. 2017;8:e3007.
11. Tong D, Liu Q, Liu G, et al. The HIF/PHF8/AR axis promotes prostate cancer progression. *Oncogenesis*. 2016;5:e283.
12. Sampson JR, Patel A, Mee AD. Multifocal renal cell carcinoma in sibs from a chromosome 9 linked (*TSC1*) tuberous sclerosis family. *Journal of medical genetics*. 1995;32:848-850.
13. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. *Am J Pathol*. 1996;149:1201-1208.
14. Kucejova B, Pena-Llopis S, Yamasaki T, et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. *Molecular cancer research : MCR*. 2011;9:1255-1265.
15. Tyburczy ME, Jozwiak S, Malinowska IA, et al. A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. *Hum Mol Genet*. 2015;24:1836-1842.
16. Alsidawi S, Kasi PM. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma. *Cold Spring Harbor molecular case studies*. 2018;4.
17. Mehra R, Vats P, Cao X, et al. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. *European urology*. 2018;74:483-486.

18. Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. *Pediatr Blood Cancer*. 2010;54:1035-1037.
19. Kubo M, Iwashita K, Oyachi N, Oyama T, Yamamoto T. Two different types of infantile renal cell carcinomas associated with tuberous sclerosis. *J Pediatr Surg*. 2011;46:E37-41.
20. Peron A, Vignoli A, La Briola F, et al. Do patients with tuberous sclerosis complex have an increased risk for malignancies? *Am J Med Genet A*. 2016;170:1538-1544.
21. Potter SL, Venkatramani R, Wenderfer S, et al. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia. *Pediatr Blood Cancer*. 2017;64.
22. Guo Y, Kwiatkowski DJ. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. *Molecular cancer research : MCR*. 2013;11:467-473.
23. Tyburczy ME, A. DK, Jennifer G, et al. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. *Plos Genetics*. 2015;11:e1005637.
24. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. *Biochemical Journal*. 2008;412:179-190.
25. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nature Reviews Molecular Cell Biology*. 2011;12:21.
26. Pawlowicz A, Wegrzyn G, Taylor K. Effect of coliphage lambda P gene mutations on the stability of the lambda O protein, the initiator of lambda DNA replication. *Acta biochimica Polonica*. 1993;40:29-31.
27. Washecka R, Hanna M. Malignant renal tumors in tuberous sclerosis. *Urology*. 1991;37:340-343.
28. Gil AT, Brett A, Cordinha C, Gomes C. Bilateral renal cell carcinoma in a paediatric patient with tuberous sclerosis complex. *BMJ Case Rep*. 2013;2013.
29. Guo J, Tretiakova MS, Troxell ML, et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. *Am J Surg Pathol*. 2014;38:1457-1467.
30. MH V, AA H, CG P, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2014;20:1955-1964.

Figure legend




Figure 1. Characterization of *TSC2* mutation-induced RCC. (A) Cross-section of the CT scan revealed an RCC in the left kidney of the patient with an arrow indicating the location of the tumor. (B) Sanger sequencing identified the *TSC2* mutations with arrows indicating the mutation sites. (C) Hematoxylin-eosin staining (100× and 400×) and immunohistochemical staining (400×) of VHL, TSC2, and p-S6K1 in the RCC samples from this patient with *TSC2* mutations and another patient with VHL syndrome.




Figure 2. The efficiency of transfection, the expression, and the effects of the wild type and mutant *TSC2*. (A) The level of *TSC2*, as well as *STAT3*, p-*STAT3*, *S6K1* and p-*S6K1* in *TSC2*-null cells transfected with plasmids expressing wild type or mutant *TSC2*. (B and C) The efficiency of transfections (B) and transcription of *TSC2* (C) when the cells were transfected with plasmids expressing wild type or mutant *TSC2*.

Table1. Published cases of RCC in patients with mutation in TSC1 or TSC2.

ID	Sex	Age at onset	Somatic/germline mutation in TSC	Loss or mutation	Mutation site	Protein	Histology	Authors and year
1	F	38	germline	LOH in TSC1	NA	NA	Clear cell renal cell carcinoma	Bjornsson et al (1996) ^[13]
2	M	23	germline	LOH in TSC1	NA	NA	Anaplastic and clear cell renal cell carcinoma	Bjornsson et al (1996) ^[13]
3	F	34	germline	LOH in TSC2	NA	NA	Anaplastic and clear cell renal cell carcinoma	Bjornsson et al (1996) ^[13]

4	M	7	Germline	Mutation in TSC2	c.1832G>A	p.R611Q	Renal cell carcinoma	Pressey et al (2010) ^[18]
5	NA	NA	Somatic	Mutation in TSC1	c.1546C>T	p.Q516X	clear cell renal cell carcinoma	Kucejova et al (2011) ^[14]
6	NA	NA	Somatic	Mutation in TSC1	IVS211-2A>T	Sp	clear cell renal cell carcinoma	Kucejova et al (2011) ^[14]
7	NA	NA	Somatic	Mutation in TSC1	c.1342C>T	p.P448S	clear cell renal cell carcinoma	Kucejova et al (2011) ^[14]
8	F	3-month	Germline	Mutation in TSC2	NA	NA	Papillary renal cell carcinoma	Kubo et al (2011) ^[19]

9	M	17-month	Germline	Mutation in TSC2	NA	NA	renal cell carcinoma	Kubo et al (2011) ^[19]
10	F	24	Germline and somatic	Mutation in TSC2	c.2714G>A (G); c.4051G>T (S);	p.R905Q(G); p.E1351 (S)	Papillary renal cell carcinoma	Tyburczy et al (2015) ^[15]
				Mutation in TSC2	c.2714G>A (G); c.4178_4179delCT (S)	p.R905Q (G);	Papillary renal cell carcinoma	Tyburczy et al (2015) ^[15]
				Mutation in TSC2	c.2714G>A (G); c.3094C>T (S)	p.R905Q (G); p.R1032 (S)	Papillary renal cell carcinoma	Tyburczy et al (2015) [15]
				Mutation in TSC2	c.2714G>A (G); c.5138G>A (S)	p.R905Q (G); p.R1713H	Papillary renal cell carcinoma	Tyburczy et al (2015) [15]

						(S)		
				LOH in	c.2714G>A (G)	p.R905Q(G)	Papillary renal	Tyburczy et
				TSC2			cell carcinoma	al (2015)
								[15]
11	M	36	Germline and	Mutation in	c.2714G>A (G);	p.R905Q (G)	Papillary renal	Tyburczy et
			somatic	TSC2	c.2355+1G>T (S)		cell carcinoma	al (2015)
								[15]
12	F	14	Germline	Mutation in	c.659T>A	NA	Renal cell	Peron et al
				TSC1			carcinoma	(2016) ^[20]
13	F	39	Germline	Mutation in	c.458T>A	NA	Chromophobe	Peron et al
				TSC1			renal cell	(2016) ^[20]
							carcinoma	
14	F	41	Germline	Mutation in	c.458T>A	NA	Chromophobe	Peron et al

				TSC1			renal cell carcinoma	(2016) ^[20]
15	F	16	Germline	Mutation in TSC1	c.547_571del25	NA	Clear cell renal cell carcinoma	Peron et al (2016) ^[20]
16	M	NA	Germline	Mutation in TSC1	c.2681_2682delAT	NA	Renal oncocytoma	Peron et al (2016) ^[20]
17	F	25	Germline	Mutation in TSC2	c.1852delC	NA	Clear cell renal cell carcinoma	Peron et al (2016) ^[20]
18	F	6	Somatic	Mutation in TSC2	c.246G>A;	p.W82X;	renal cell carcinoma	Potter et al (2017) ^[21]
19	M	47	Germline	Mutation in	c.4859A>G	p.H1620R	papillary RCC	Alsidawi et

				TSC2	c.4949A>G	p.Y1650C		al	
									(2018) ^[16]
20	NA	NA	Somatic	Mutation in	NA	p.L741fs	eosinophilic	Mehra et al	
				TSC2		p.K533Splice	solid and		(2018) ^[17]
							cystic RCC		
21	NA	NA	Somatic	LOH in	NA	p.C519fs	eosinophilic	Mehra et al	
				TSC2			solid and		(2018) ^[17]
							cystic RCC		
22	NA	NA	Somatic	LOH in	NA	p.Y349fs	eosinophilic	Mehra et al	
				TSC2			solid and		(2018) ^[17]
							cystic RCC		
23	NA	NA	Somatic	Mutation in	NA	p.L773*	eosinophilic	Mehra et al	
				TSC2		p.N1250fs	solid and		(2018) ^[17]

							cystic RCC	
24	NA	NA	Somatic	Nonsense	NA	p.S9*	eosinophilic	Mehra et al
							solid and	(2018) ^[17]
							cystic RCC	
25	NA	NA	Somatic	LOH in TSC1	NA	p.Y176fs	eosinophilic	Mehra et al
							solid and	(2018) ^[17]
							cystic RCC	
26	NA	NA	Somatic	Mutation in TSC1	NA	p.Q653* p.Q696fs	eosinophilic	Mehra et al
							solid and	(2018) ^[17]
							cystic RCC	

Abbreviations: F: Female, G: Germline, LOH: Loss of heterozygosity; M: male; NA: Not Available; S: Somatic; TSC: Tuberous Sclerosis Complex.